GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

Launched by W.L.GORE & ASSOCIATES · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medical device called the GORE® Ascending Stent Graft (ASG) to see how safe and effective it is for treating a specific type of heart condition known as de novo Type A aortic dissection. This condition occurs when there is a tear in the inner layer of the aorta, the large blood vessel that carries blood from the heart. The trial aims to help patients who are at high risk for traditional surgery due to their age or other health issues.

To participate, individuals generally need to be at least 18 years old and diagnosed with a Type A aortic dissection within the last 30 days. Key eligibility criteria include having specific measurements of the aorta and being considered at high risk for open surgery for various reasons, such as being over 80 years old or having significant respiratory issues. Participants will need to sign a consent form and agree to follow-up visits and imaging tests for up to five years. While the trial is not yet recruiting, it will provide an important opportunity for patients who may benefit from this innovative treatment approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria - Primary Arm:
• The subject is/has:
• • 1. De novo Type A aortic dissection (≤30 days from symptom onset to index endovascular procedure) compatible with the treatment requirements of the ASG device.
• • 2. Primarily intended to be treated by placement of the ASG device in the ascending aorta. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.
• 3. Anatomic compatibility of the ascending aorta required for implanting the ASG device:
• • a) Proximal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium.
• • ii. Total aortic diameter between 27mm - 48mm iii. Landing zone cannot be heavily calcified or thrombosed. b) Distal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium.
• • c) Adequate aortic length
• 4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:
• • 1. ≥80 years of age
• • 2. Body mass index (BMI) ≥ 35 kg/m2
• • 3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised pulmonary function tests (PFT) on spirometry or other factors as determined by the Investigator)
• • 4. Prior Cardiac Surgery
• • 5. Hostile Chest (VARC-2 Definition)
• • 6. Clinical Frailty Scale 3-7
• • 7. Clinical malperfusion (head, gut, lower extremity)
• • 8. Transfusion is not possible (e.g., Jehovah's Witness)
• • 9. Renal Dialysis prior to aortic dissection
• • 10. Chronic renal insufficiency (eGFR\<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
• • 5. Age ≥18 years at time of informed consent signature.
• • 6. Adequate vascular access via transfemoral or retroperitoneal approach.
• • 7. Informed Consent Form (ICF) signed by the subject or legally authorized representative.
• • 8. Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows.
• • Exclusion Criteria - Primary Arm
• The subject is/has:
• • 1. Mechanical heart valve in the aortic position.
• • 2. Aortic insufficiency grade 3 or greater confirmed during TEE pre-implant.
• • 3. Indwelling intravascular device that would interfere with or result in contact with planned repair (e.g., contiguous arch graft, LVAD, TAVR device in continuity with aortic tear).
• • 4. Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome).
• • 5. Participation in investigational drug or medical device study within one year of enrollment unless approved by the Sponsor.
• • 6. Known history of drug abuse within one year of treatment which would affect the ability to obtain follow-up.
• • 7. Pregnant at time of procedure.
• • 8. Active infected aorta, mycotic aneurysm.
• • 9. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).
• • 10. Life expectancy \<12 months due to presence of another comorbid condition.
• • 11. Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \[HIT-2\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device).
• • 12. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.
• • 13. Coronary malperfusion.
• • 14. Catastrophic neurological complications in the 30 days prior to the dissection diagnosis (e.g., progressively worsening symptoms, coma, Glasgow Coma Scale \<=8).
• • 15. Aortic fistula.
• • 16. In circulatory shock (e.g., systolic blood pressure \<80 mmHg without inotropes, base deficit \> -10 mmol/L or -10 mEq/L) at any time prior to the initiation of the index endovascular procedure.
• • 17. In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at any time prior to the initiation of the index endovascular procedure.
• • 18. Clinical or radiographic signs of bowel infarction, gastrointestinal hemorrhage, or bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis) at any time prior to the initiation of the index endovascular procedure.
• • Inclusion Criteria - Secondary Arm
• The subject is/has:
• • 1. De novo Type A aortic dissection (≤90 days from symptom onset until first study procedure) compatible with the treatment requirements of the ASG device alone or the ASG device in combination with the TBE device in the Zone 0 position.
• • 2. Primarily intended to be treated by placement of the ASG device in the ascending aorta or ASG device in combination with the TBE device in the ascending aorta and aortic arch. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.
• • 3. Anatomic requirements for intended treatment with the ASG device alone or in combination with the TBE device.
• a) Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device alone) i. Proximal Aortic Landing Zone:
• • 1. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium.
• • 2. Total aortic diameter between 27mm - 48mm.
• 3. Landing zone cannot be heavily calcified or thrombosed. ii. Distal Aortic Landing Zone:
• • <!-- -->
• • 1. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium.
• • iii. Adequate aortic length
• 2. Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device and TBE device) i. Proximal Aortic Landing Zone:
• • <!-- -->
• • 1. Primary entry tear must be identified in Zone 0-5.
• • 2. Landing zone is native aorta.
• • 3. Primary entry tear location is ≥2cm distal to the most distal coronary artery ostium.
• • 4. Proximal landing zone must be ≥2cm in the ascending aorta.
• • 5. Landing zone cannot be heavily calcified or thrombosed.
• 6. Total aortic landing zone diameter 27mm - 48mm. ii. Branch Vessel Landing Zone:
• • <!-- -->
• • 1. Length of ≥2.5 cm proximal to first major branch vessel.
• • 2. Target branch vessel inner diameters of 11-18 mm.
• • 3. Target branch vessel landing zone must be in native vessel that cannot be heavily calcified or thrombosed.
• • 4. The distal 15mm landing zone cannot be dissected.
• 4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:
• • 1. ≥80 years of age
• • 2. BMI ≥ 35 kg/m2
• • 3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised PFTs on spirometry or other factors as determined by the Investigator)
• • 4. Prior Cardiac Surgery
• • 5. Hostile Chest (VARC-2 Definition)
• • 6. Clinical Frailty Scale 3-9
• • 7. Clinical malperfusion (head, gut, lower extremity)
• • 8. Transfusion is not possible (e.g., Jehovah's Witness)
• • 9. Renal Dialysis prior to aortic dissection
• • 10. Chronic renal insufficiency (eGFR\<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
• • 5. Age ≥18 years at time of informed consent signature.
• • 6. Adequate vascular access via transfemoral or retroperitoneal approach.
• • 7. Informed Consent Form (ICF) signed by the subject or legally authorized representative.
• • 8. Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows.
• Exclusion Criteria - Secondary Arm:
• The subject is/has:
• • 1. Mechanical heart valve in the aortic position.
• • 2. Pregnant at time of procedure.
• • 3. Active infected aorta, mycotic aneurysm.
• • 4. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).
• • 5. Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \[HIT-2\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device).
• • 6. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.